Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3

Table 3 Virological response between the two treatment groups at 48 weeks

	Percentage of patients who achieved HIV RNA< 50 copies/ml		Relative Risk, 95% confidence interval	P value
	Group A	Group B
ITT*	71.7% (86/120)	75.0% (63/84)	0.843, 0.447–1.589	0.633
OT**	90.6% (87/96)	96.9% (63/65)	0.303, 0.063–1.453	0.202

ISSN: 1742-6405